

IHI Call Days | Call 9

Advancing Personalized Therapies for Metastatic Colorectal Cancer through Patient-Derived Organoids

Contact person name: Associate Prof Ahmet Acar

Organisation: Middle East Technical University, Ankara, Turkey

E-mail: acara@metu.edu.tr

Link to the IHI brokerage platform:

- https://ihicalldays2024.converve.io/regm_60ff7e77363ed173281964008286ef6fba55154a05ac97358e03fbf4b649653f

Challenges and objectives

- Lack of reliable preclinical models and limited personalized therapy options for mCRC.
- SO5: Enable the development of new and improved evaluation methodologies and models.
- Limited availability of effective, personalized treatment options for metastatic colorectal cancer (mCRC)



Your approach to solve the problem

- Characterizing PDOs
- Ensuring Genomic Stability
- High-Content Drug Screening
- Developing New Evaluation Methodologies

Is your project suitable for IHI?

- Public-private partnership is essential to integrate scientific, technological, and commercial expertise (accessing to cutting-edge technology and resources/Scaling up for clinical and commercial impact)
- Pharmaceutical and biotech companies (high-content drug screening, drug development pipelines)
- Medical devices and laboratory automation (PDO culturing and screening technologies, 3D bioprinting)

Outcomes and Impact

- Personalized Treatment Options for mCRC Patients via acceleration of drug development and clinical translation
- Collaboration with healthcare providers, public-private partnerships, standards compliance, scalability and cost-effectiveness, long-term partnerships.
- Strengthening the European health research ecosystem and global leadership in precision oncology
- Enhancing patient outcomes and healthcare efficiency; and hence, reducing healthcare costs



Expertise and resources

- We have:
 - Extensive expertise in Patient-Derived Organoid Technology
- We are looking for:
 - Pharmaceutical industry and SME collaborations.

